DISCOVER
Managed Access Programmes
Our technological innovation platform called “CleanWeb-MAP” (CleanWeb Managed Access Programme) facilitates access to new drugs by eligible patients.
There are multiple terms that fall under the umbrella of MAP, including Compassionate Use, Early Access, Named Patient Use and Individual Patient Request Programmes to name but a few. The terms used may vary from country to country depending on local laws and regulations. Our module is closely linked to our CleanWeb software platform for medical data collection, it enables self-registration of prescribing physicians and pharmacists, for each new product related to MAP.
Ethical and compliant
mechanism of access to drugs
• MAPs provide alternative treatments to patients with life-threatening diseases with no therapeutic options
• CleanWeb-MAP meets local laws and regulations Seamless Managed Access Programmes
Entrust your project
to our expert
data management team
Drug use outcome
in a real-world setting
Allows you to gain valuable early experience with a product
CleanWeb-MAP facilitates the management of MAPs in real-life conditions
CleanWeb-MAP:
streamlined interactions with stakeholders
Each role and access are clearly defined Physicians, Nurses, Medical Advisor, Programme Manager, Pharmacovigilance officer, Logistics perfectly interact in the MAP cycle process.
The ordering process and the availability of drugs are assured in interaction with any external system and data source.
CleanWeb-MAP allows for the involvement of other stakeholders and for the integration of many additional behaviours (e.g., Pharmacist).
Do you want to learn more about our e-health solution? Just fill in the form and we will get back to you shortly
A LEADING POSITION AND
AN INTERNATIONAL DEPLOYMENT
64 +
countries
involved
20 000 +
investigational
Centres
3 million +
patients
in database
50 000 +
users
worlwide
LATEST NEWSOUR NEWS >
February 27, 2025
18 – 20 march – Basel, Switzerland Register Now DIA Europe 2025 will focus on sustainability, innovation and collaboration – three key pillars for shaping the future of healthcare. From the environmental impact of pharmaceuticals and of the drug development lifecycle to sustainable partnerships and sustainable healthcare systems, DIA Europe 2025 will be the prime opportunity to discuss how collaboration and […]
February 27, 2025
Med City News From the executive boardrooms of pharma companies to academic research centers, one fact is becoming unmistakably clear: making radiopharmaceuticals is an inherently complex, high-stakes endeavor, and the industry is racing to manage the risks of these perishable therapies before the clock runs out. Somewhere in a laboratory, tucked away in its vessel, […]
February 27, 2025
Applied Clinical Trials Artificial intelligence (AI) is the biggest transformation in life sciences in the last 25 years—an advancement akin to mapping the human genome, with potential for a much higher rate of scientific breakthroughs over the next decade. But there’s still a lot to consider when applying AI to clinical development and product commercialization, […]